European Hematology Association (EHA) Congress, June 13 -16, 2024

Zasoby na tej stronie

Pobierz zasoby

• plik pdf

  RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.

  Pobierz
• plik pdf

  Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.

  Pobierz
• plik pdf

  CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.

  Pobierz